Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137)
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma
Summary
This guidance has been updated and replaced by Lymphoma (follicular non-Hodgkin's) - rituximab.
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA37
Issued: March 2002
How this guidance was produced